• Home
  • NTC S.r.l.
  • EDEDAY – EDENIGHT: HYPERTONIC 0.4% HYALURONIC ACID (OPHTHALMOLOGY - CORNEAL EDEMA)

EDEDAY – EDENIGHT: HYPERTONIC 0.4% HYALURONIC ACID (OPHTHALMOLOGY - CORNEAL EDEMA)

EDEDAY – EDENIGHT: HYPERTONIC 0.4% HYALURONIC ACID (OPHTHALMOLOGY - CORNEAL EDEMA)
Product Description

Ededay and Edenight are hypertonic products containing sodium hyaluronate 0.4% and hypertonic agents, indicated for the temporary relief of the symptoms of corneal edema. Ededay eye drops also contains sorbitol (13,5%) and can be used during the day.          Edenight ointment contains sodium chloride (4.5%) and is suitable for a night application. The application results into an increased saline concentration of tear film and consequently a recall of water from the corneal layers towards the surface.  Sodium hyaluronate provides protection and hydration and makes the application of hypertonic ointment more comfortable. Ededay and Edenight can help to accelerate postoperative recovery, with a reduction in corneal edema and an improvement in visual function.
- Presentation: 10ml Novelia bottle; 5 gr Tube.
- Class: Medical Device
- CE Mark expiry date: 2024

4 Scientific publication available

Read more Show less

NTC S.r.l.

  • IT
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Italy
More specifications Fewer specifications

NTC S.r.l.

  • IT
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile

More Products from NTC S.r.l. (29)

show all 29 other products

NTC S.r.l. resources (9)

  • NTC expands into pediatric allergology

    News NTC expands into pediatric allergology

    NTC Srl, R&D driven pharmaceutical companywith headquarters in Italy focused in ophthalmology, announces results from apolycentric study on Lertal®, a multicomponent nutraceutical, as add-on treatmentin children with allergic rhinoconjunctivitis (AR).
    3 Sep 2019
  • Therapeutical areas - brochure

    Brochure Therapeutical areas - brochure

    Advanced scientific research and technology drive our efforts to innovate care practices.
    Our range of products builds from our historical vocation for innovation aimed at improving the experience of patients and healthcare practices.
    An innovation aimed at discovering specific therapeutic gestures: simple and intuitive,  sustainable, and technically advanced for empowering the patient.
    Our research aims to put pioneering new products within the reach of everyone and to optimize the
    performance of our products by analyzing the daily needs and habits of people undergoing treatment.
    We research, develop and produce innovative drugs, medical devices and food supplements.
    We market our products worldwide through licensing, distribution, marketing, and commercial deals with partner companies.
    Our core therapeutic areas are: Ophthalmology, Gastro-Metabolism, Pediatrics and Gynacology.

  • NTC news: Post-cataract surgery

    News NTC news: Post-cataract surgery

    Last June, in Milan, NTC held a very important Investigators’ Meeting of two pivotal registration studies for a novel drug indicated in post cataract surgery: over 50 centers were involved in such large clinical effort and attended the event.
    23 Jul 2019
  • NTC: Novelty

    Video NTC: Novelty

    NTC: Novelty
    2023-10-05
  • NTC: Technology

    Video NTC: Technology

    NTC Technology
    2023-10-05
  • NTC: Care

    Video NTC: Care

    NTC Care
    2023-10-05
  • Value Report 2022

    Brochure Value Report 2022

    We focus on Novelty, Technology and we Care of our partners, customers, patients and of our people.

    The following information is intended for healthcare professionals only.

  • Value Report 2021

    Brochure Value Report 2021

    In NTC, we research, develop and produce innovative drugs, medical devices and food supplements.
    We market our products worldwide through licensing, distribution, marketing, and
    commercial deals with partner companies.
    In 2020, NTC consolidated its leadership in its fields of specialization by expanding its
    partnership network into Europe and Asia.
    Read more!
  • VALUE REPORT 2020

    Brochure VALUE REPORT 2020

    As a global player in the area of B2B, NTC is present in almost 100 countries and workwith around 200 partner companies. In addition, it carries out direct commercial activities (B2C) in the field of Ophthalmology in Italy and Spain.Dedicated to creating sustainable value, NTC has integrated social and environmentalconsiderations into its business operations and into its dealings with stakeholders. As partof its commitment to Corporate Social Responsibility, NTC has embedded internationalguidelines and procedures in its processes and practices.